# Nektar Therapeutics (NKTR) — Analyst Forecast

NKTR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nktr/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 1 | 0 | 11 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $50.00 | $116.29 | $185.00 | 7 |

Last price $37.72 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | UBS | Initiated Coverage | Neutral | $53.00 |
| Oct 12, 2026 | Leerink Partners | Initiated Coverage | Outperform | $130.00 |
| Oct 9, 2026 | BTIG | Maintained | Buy | $178.00 |
| Oct 9, 2026 | Raymond James | Initiated Coverage | Market Perform | — |
| Oct 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $185.00 |
| Sep 28, 2026 | BTIG | Maintained | Buy | $178.00 |
| Sep 25, 2026 | BTIG | Maintained | Buy | $178.00 |
| Sep 23, 2026 | Wedbush | Maintained | Neutral | $50.00 |
| Sep 16, 2026 | BTIG | Maintained | Buy | $178.00 |
| Sep 9, 2026 | BTIG | Maintained | Buy | $178.00 |
| Aug 21, 2026 | JP Morgan | Maintained | Neutral | $65.00 |
| Jul 22, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $153.00 |
| May 11, 2026 | Wedbush | Maintained | Neutral | $80.00 |
| May 8, 2026 | Piper Sandler | Maintained | Overweight | $192.00 |
| Apr 21, 2026 | Wedbush | Maintained | Neutral | $95.00 |
| Apr 21, 2026 | Citigroup | Maintained | Buy | $151.00 |
| Apr 20, 2026 | HC Wainwright & Co. | Maintained | Buy | $185.00 |
| Apr 20, 2026 | BTIG | Maintained | Buy | $178.00 |
| Mar 24, 2026 | Wedbush | Initiated Coverage | Neutral | $70.00 |
| Mar 17, 2026 | TD Cowen | Initiated Coverage | Buy | — |

## Frequently Asked Questions

### What is the price target for NKTR stock?

The average 12-month analyst price target for Nektar Therapeutics (NKTR) is $116.29, with a high estimate of $185.00 and a low of $50.00, across 7 analysts.

### Is NKTR a buy, sell, or hold?

Analysts covering Nektar Therapeutics currently average a Buy rating: 10 buy, 1 hold and 0 sell, from 11 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for NKTR?

The average price target of $116.29 implies 208.29% upside from the last price of $37.72.

### What is the latest analyst rating on NKTR?

On Oct 12, 2026, UBS initiated coverage of Nektar Therapeutics at Neutral with a price target of $53.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).